|
ENGN enGene Therapeutics Inc 1980845 |
| Income Statement |
|
Net Income
|
2026-04-30
|
$-30,227,000.00 |
| Balance Sheet |
|
Current Assets
|
$270,000,000.00 |
|
Assets
|
$307,524,000.00 |
|
Current Liabilities
|
$21,485,000.00 |
|
Liabilities
|
$52,356,000.00 |
|
Equity
|
$255,168,000.00 |
|
Shares Out
|
66989466.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-59,401,000.00 |
|
Investing Cash Flow
|
$-102,659,000.00 |
| Market Analysis |
Market Cap
|
$117,901,460.16 |
|
Price
|
$1.77 |
|
BVPS
|
3.81 |
|
PB
|
0.46 |
|
EPS
|
-0.43 |
|
FCF
|
$-59,652,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:37 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:35 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view ENGN documents filed with the SEC.
ENGN Filings
Clear
